Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 15 August 1997:
Vol. 277. no. 5328, pp. 959 - 965
DOI: 10.1126/science.277.5328.959
Prev | Table of Contents | Next

Reports

Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression

Michael W. Smith, * Michael Dean, * Mary Carrington, * Cheryl Winkler, Gavin A. Huttley, Deborah A. Lomb, James J. Goedert, Thomas R. O'Brien, Lisa P. Jacobson, Richard Kaslow, Susan Buchbinder, Eric Vittinghoff, David Vlahov, Keith Hoots, Margaret W. Hilgartner, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study, Stephen J. O'Brien dagger

The critical role of chemokine receptors (CCR5 and CXCR4) in human immunodeficiency virus-type 1 (HIV-1) infection and pathogenesis prompted a search for polymorphisms in other chemokine receptor genes that mediate HIV-1 disease progression. A mutation (CCR2-64I) within the first transmembrane region of the CCR2 chemokine and HIV-1 receptor gene is described that occurred at an allele frequency of 10 to 15 percent among Caucasians and African Americans. Genetic association analysis of five acquired immunodeficiency syndrome (AIDS) cohorts (3003 patients) revealed that although CCR2-64I exerts no influence on the incidence of HIV-1 infection, HIV-1-infected individuals carrying the CCR2-64I allele progressed to AIDS 2 to 4 years later than individuals homozygous for the common allele. Because CCR2-64I occurs invariably on a CCR5-+-bearing chromosomal haplotype, the independent effects of CCR5-Delta 32 (which also delays AIDS onset) and CCR2-64I were determined. An estimated 38 to 45 percent of AIDS patients whose disease progresses rapidly (less than 3 years until onset of AIDS symptoms after HIV-1 exposure) can be attributed to their CCR2-+/+ or CCR5-+/+ genotype, whereas the survival of 28 to 29 percent of long-term survivors, who avoid AIDS for 16 years or more, can be explained by a mutant genotype for CCR2 or CCR5.

M. W. Smith, M. Carrington, C. Winkler, D. A. Lomb, Science Applications International Corp. Frederick, National Cancer Institute, Frederick, MD 21702-1201, USA.
M. Dean, G. A. Huttley, S. J. O'Brien, Laboratory of Genomic Diversity, National Cancer Institute, Frederick, MD 21702-1201, USA.
J. J. Goedert and T. R. O'Brien, Viral Epidemiology Branch, National Cancer Institute-Executive Plaza North, 6130 Executive Boulevard, Bethesda, MD 20892, USA.
L. P. Jacobson, Department of Epidemiology, The Johns Hopkins University School of Hygiene and Public Health, Room E-7008, 615 North Wolfe Street, Baltimore, MD 21205-1999, USA.
R. Kaslow, Department of Epidemiology, University of Alabama at Birmingham, 720 South 20th Street, Tidwell Hall 212C, Birmingham, AL 35294, USA.
S. Buchbinder and E. Vittinghoff, AIDS Office, Department of Public Health, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102-6033, USA.
D. Vlahov, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Room E-6008, 615 North Wolfe Street, Baltimore, MD 21205, USA.
K. Hoots, Departments of Pediatrics and Internal Medicine, University of Texas Medical School at Houston, Houston, TX 77030, USA.
M. W. Hilgartner, Division of Pediatric Hematology and Oncology, New York Hospital-Cornell Medical Center, 525 East 68th Street, Payson 695, New York, NY 10021, USA.
*   These authors contributed equally to this study.

dagger    To whom correspondence should be addressed. E-mail: obrien{at}ncifcrf.gov

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Differential natural killer cell mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes.
G. Alter, M. P. Martin, N. Teigen, W. H. Carr, T. J. Suscovich, A. Schneidewind, H. Streeck, M. Waring, A. Meier, C. Brander, et al. (2007)
J. Exp. Med. 204, 3027-3036
   Abstract »    Full Text »    PDF »
Genetic Susceptibility, HIV Infection, and the Kidney.
K. Kiryluk, J. Martino, and A. G. Gharavi (2007)
Clin. J. Am. Soc. Nephrol. 2, S25-S35
   Abstract »    Full Text »    PDF »
Genetic Protection against Hepatitis B Virus Conferred by CCR5{Delta}32: Evidence that CCR5 Contributes to Viral Persistence.
C. L. Thio, J. Astemborski, A. Bashirova, T. Mosbruger, S. Greer, M. D. Witt, J. J. Goedert, M. Hilgartner, A. Majeske, S. J. O'Brien, et al. (2007)
J. Virol. 81, 441-445
   Abstract »    Full Text »    PDF »
CD8+ and CD20+ Lymphocytes Cooperate To Control Acute Simian Immunodeficiency Virus/Human Immunodeficiency Virus Chimeric Virus Infections in Rhesus Monkeys: Modulation by Major Histocompatibility Complex Genotype.
H. Mao, B. A. P. Lafont, T. Igarashi, Y. Nishimura, C. Brown, V. Hirsch, A. Buckler-White, R. Sadjadpour, and M. A. Martin (2005)
J. Virol. 79, 14887-14898
   Abstract »    Full Text »    PDF »
Use of a Combined Ex Vivo/In Vivo Population Approach for Screening of Human Genes Involved in the Human Immunodeficiency Virus Type 1 Life Cycle for Variants Influencing Disease Progression.
G. Bleiber, M. May, R. Martinez, P. Meylan, J. Ott, J. S. Beckmann, A. Telenti, and the Swiss HIV Cohort Study (2005)
J. Virol. 79, 12674-12680
   Abstract »    Full Text »    PDF »
Combined Effect of CCR5-{Delta}32 Heterozygosity and the CCR5 Promoter Polymorphism -2459 A/G on CCR5 Expression and Resistance to Human Immunodeficiency Virus Type 1 Transmission.
F. Hladik, H. Liu, E. Speelmon, D. Livingston-Rosanoff, S. Wilson, P. Sakchalathorn, Y. Hwangbo, B. Greene, T. Zhu, and M. J. McElrath (2005)
J. Virol. 79, 11677-11684
   Abstract »    Full Text »    PDF »
Major Histocompatibility Complex Class II (HLA-DRB and -DQB) Allele Frequencies in Botswana: Association with Human Immunodeficiency Virus Type 1 Infection.
T. Ndung'u, S. Gaseitsiwe, E. Sepako, F. Doualla-Bell, T. Peter, S. Kim, I. Thior, V. A. Novitsky, and M. Essex (2005)
Clin. Vaccine Immunol. 12, 1020-1028
   Abstract »    Full Text »    PDF »
Heterodimerization of G Protein-Coupled Receptors: Specificity and Functional Significance.
S. C. Prinster, C. Hague, and R. A. Hall (2005)
Pharmacol. Rev. 57, 289-298
   Abstract »    Full Text »    PDF »
The CCR5-{Delta}32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source.
C Goulding, A Murphy, G MacDonald, S Barrett, J Crowe, J Hegarty, S McKiernan, and D Kelleher (2005)
Gut 54, 1157-1161
   Abstract »    Full Text »    PDF »
Effectiveness of Highly Active Antiretroviral Therapy among Injection Drug Users with Late-Stage Human Immunodeficiency Virus Infection.
D. Vlahov, N. Galai, M. Safaeian, S. Galea, G. D. Kirk, G. M. Lucas, and T. R. Sterling (2005)
Am. J. Epidemiol. 161, 999-1012
   Abstract »    Full Text »    PDF »
Study of C-C Chemokine Receptor 2 Alleles in Sarcoidosis, with Emphasis on Family-based Analysis.
R. Valentonyte, J. Hampe, P. J. P. Croucher, J. Muller-Quernheim, E. Schwinger, S. Schreiber, and M. Schurmann (2005)
Am. J. Respir. Crit. Care Med. 171, 1136-1141
   Abstract »    Full Text »    PDF »
Bioluminescence Resonance Energy Transfer Reveals Ligand-induced Conformational Changes in CXCR4 Homo- and Heterodimers.
Y. Percherancier, Y. A. Berchiche, I. Slight, R. Volkmer-Engert, H. Tamamura, N. Fujii, M. Bouvier, and N. Heveker (2005)
J. Biol. Chem. 280, 9895-9903
   Abstract »    Full Text »    PDF »
Breast Cancer Progression and Host Polymorphisms in the Chemokine System: Role of the Macrophage Chemoattractant Protein-1 (MCP-1) -2518 G Allele.
G. Ghilardi, M. L. Biondi, A. La Torre, L. Battaglioli, and R. Scorza (2005)
Clin. Chem. 51, 452-455
   Full Text »    PDF »
Evidence for Negative Binding Cooperativity within CCR5-CCR2b Heterodimers.
L. El-Asmar, J.-Y. Springael, S. Ballet, E. U. Andrieu, G. Vassart, and M. Parmentier (2005)
Mol. Pharmacol. 67, 460-469
   Abstract »    Full Text »    PDF »
Chemokines in the Pathogenesis of Vascular Disease.
I. F. Charo and M. B. Taubman (2004)
Circ. Res. 95, 858-866
   Abstract »    Full Text »    PDF »
Atherosclerosis in Patients Infected With HIV Is Influenced by a Mutant Monocyte Chemoattractant Protein-1 Allele.
C. Alonso-Villaverde, B. Coll, S. Parra, M. Montero, N. Calvo, M. Tous, J. Joven, and L. Masana (2004)
Circulation 110, 2204-2209
   Abstract »    Full Text »    PDF »
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification.
T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth (2004)
Endocr. Rev. 25, 629-672
   Abstract »    Full Text »    PDF »
PSC-RANTES Blocks R5 Human Immunodeficiency Virus Infection of Langerhans Cells Isolated from Individuals with a Variety of CCR5 Diplotypes.
T. Kawamura, S. E. Bruce, A. Abraha, M. Sugaya, O. Hartley, R. E. Offord, E. J. Arts, P. A. Zimmerman, and A. Blauvelt (2004)
J. Virol. 78, 7602-7609
   Abstract »    Full Text »    PDF »
Mycobacterium tuberculosis-Induced CXCR4 and Chemokine Expression Leads to Preferential X4 HIV-1 Replication in Human Macrophages.
Y. Hoshino, D. B. Tse, G. Rochford, S. Prabhakar, S. Hoshino, N. Chitkara, K. Kuwabara, E. Ching, B. Raju, J. A. Gold, et al. (2004)
J. Immunol. 172, 6251-6258
   Abstract »    Full Text »    PDF »
Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer.
A Zafiropoulos, N Crikas, A M Passam, and D A Spandidos (2004)
J. Med. Genet. 41, e59
   Full Text »    PDF »
Induction of Autoantibodies to CCR5 in Macaques and Subsequent Effects upon Challenge with an R5-Tropic Simian/Human Immunodeficiency Virus.
B. Chackerian, L. Briglio, P. S. Albert, D. R. Lowy, and J. T. Schiller (2004)
J. Virol. 78, 4037-4047
   Abstract »    Full Text »    PDF »
Patterns of ethnic diversity among the genes that influence AIDS.
C. Winkler, P. An, and S. J. O'Brien (2004)
Hum. Mol. Genet. 13, R9-19
   Abstract »    Full Text »    PDF »
Analysis of the involvement of CCR5-{Delta}32 and CCR2-V64I variants in the development of endometriosis.
G. Antinolo, R.M. Fernandez, J.A. Noval, J.L. Molini, and S. Borrego (2004)
Mol. Hum. Reprod. 10, 155-157
   Abstract »    Full Text »    PDF »
Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3.
A. G. Gharavi, T. Ahmad, R. D. Wong, R. Hooshyar, J. Vaughn, S. Oller, R. Z. Frankel, L. A. Bruggeman, V. D. D'Agati, P. E. Klotman, et al. (2004)
PNAS 101, 2488-2493
   Abstract »    Full Text »    PDF »
Fraction of Cases of Acquired Immunodeficiency Syndrome Prevented by the Interactions of Identified Restriction Gene Variants.
M. J. Silverberg, M. W. Smith, J. S. Chmiel, R. Detels, J. B. Margolick, C. R. Rinaldo, S. J. O'Brien, and A. Munoz (2004)
Am. J. Epidemiol. 159, 232-241
   Abstract »    Full Text »    PDF »
Relationship between In Vitro Human Immunodeficiency Virus Type 1 Replication Rate and Virus Load in Plasma.
T. B. Campbell, K. Schneider, T. Wrin, C. J. Petropoulos, and E. Connick (2003)
J. Virol. 77, 12105-12112
   Abstract »    Full Text »    PDF »
R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms.
T. Kawamura, F. O. Gulden, M. Sugaya, D. T. McNamara, D. L. Borris, M. M. Lederman, J. M. Orenstein, P. A. Zimmerman, and A. Blauvelt (2003)
PNAS 100, 8401-8406
   Abstract »    Full Text »    PDF »
Comparing the Ex Vivo Fitness of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates of Subtypes B and C.
S. C. Ball, A. Abraha, K. R. Collins, A. J. Marozsan, H. Baird, M. E. Quinones-Mateu, A. Penn-Nicholson, M. Murray, N. Richard, M. Lobritz, et al. (2002)
J. Virol. 77, 1021-1038
   Abstract »    Full Text »    PDF »
Importance of B-Cell Responses for Immunological Control of Variant Strains of Simian Immunodeficiency Virus.
W. E. Johnson, J. D. Lifson, S. M. Lang, R. P. Johnson, and R. C. Desrosiers (2002)
J. Virol. 77, 375-381
   Abstract »    Full Text »    PDF »
Val64Ile Polymorphism in the C-C Chemokine Receptor 2 Is Associated With Reduced Coronary Artery Calcification.
A. M. Valdes, M. L. Wolfe, E. J. O'Brien, N. K. Spurr, W. Gefter, A. Rut, P. H.E. Groot, and D. J. Rader (2002)
Arterioscler. Thromb. Vasc. Biol. 22, 1924-1928
   Abstract »    Full Text »    PDF »
A Monocyte Chemoattractant Protein-1 (MCP-1) Polymorphism And Outcome After Renal Transplantation.
B. Kruger, B. Schroppel, R. Ashkan, B. Marder, C. Zulke, B. Murphy, B. K. Kramer, and M. Fischereder (2002)
J. Am. Soc. Nephrol. 13, 2585-2589
   Abstract »    Full Text »    PDF »
MHC Class I Alleles Influence Set-Point Viral Load and Survival Time in Simian Immunodeficiency Virus-Infected Rhesus Monkeys.
T. Muhl, M. Krawczak, P. ten Haaft, G. Hunsmann, and U. Sauermann (2002)
J. Immunol. 169, 3438-3446
   Abstract »    Full Text »    PDF »
Upregulation of Surface Feline CXCR4 Expression following Ectopic Expression of CCR5: Implications for Studies of the Cell Tropism of Feline Immunodeficiency Virus.
B. J. Willett, C. A. Cannon, and M. J. Hosie (2002)
J. Virol. 76, 9242-9252
   Abstract »    Full Text »    PDF »
Cell surface receptors, virus entry and tropism of primate lentiviruses.
P. R. Clapham and A. McKnight (2002)
J. Gen. Virol. 83, 1809-1829
   Abstract »    Full Text »    PDF »
Commentary: Meta-analysis of Individual Participants' Data in Genetic Epidemiology.
J. P. A. Ioannidis, P. S. Rosenberg, J. J. Goedert, and T. R. O'Brien (2002)
Am. J. Epidemiol. 156, 204-210
   Full Text »    PDF »
Modulating influence on HIV/AIDS by interacting RANTES gene variants.
P. An, G. W. Nelson, L. Wang, S. Donfield, J. J. Goedert, J. Phair, D. Vlahov, S. Buchbinder, W. L. Farrar, W. Modi, et al. (2002)
PNAS 99, 10002-10007
   Abstract »    Full Text »    PDF »
Rhesus Macaque Resistance to Mucosal Simian Immunodeficiency Virus Infection Is Associated with a Postentry Block in Viral Replication.
B. Peng, R. Voltan, L. Lim, Y. Edghill-Smith, S. Phogat, D. S. Dimitrov, K. Arora, M. Leno, S. Than, R. Woodward, et al. (2002)
J. Virol. 76, 6016-6026
   Abstract »    Full Text »    PDF »
A Human Immunodeficiency Virus Type 1 Isolate from an Infected Person Homozygous for CCR5{Delta}32 Exhibits Dual Tropism by Infecting Macrophages and MT2 Cells via CXCR4.
H. M. Naif, A. L. Cunningham, M. Alali, S. Li, N. Nasr, M. M. Buhler, D. Schols, E. de Clercq, and G. Stewart (2002)
J. Virol. 76, 3114-3124
   Abstract »    Full Text »    PDF »
Chemokine Receptor Polymorphism and Risk of Acute Rejection in Human Renal Transplantation.
R. Abdi, T. Thi Bich Huong, A. Sahagun-Ruiz, P. M. Murphy, B. M. Brenner, E. L. Milford, and D. H. McDermott (2002)
J. Am. Soc. Nephrol. 13, 754-758
   Abstract »    Full Text »    PDF »
Distribution of Chemokine Receptor CCR2 and CCR5 Genotypes and Their Relative Contribution to Human Immunodeficiency Virus Type 1 (HIV-1) Seroconversion, Early HIV-1 RNA Concentration in Plasma, and Later Disease Progression.
J. Tang, B. Shelton, N. J. Makhatadze, Y. Zhang, M. Schaen, L. G. Louie, J. J. Goedert, E. C. Seaberg, J. B. Margolick, J. Mellors, et al. (2002)
J. Virol. 76, 662-672
   Abstract »    Full Text »    PDF »
Chemokine Receptor Genotype Is Associated With Diabetic Nephropathy in Japanese With Type 2 Diabetes.
K. Nakajima, Y. Tanaka, T. Nomiyama, T. Ogihara, L. Piao, K. Sakai, T. Onuma, and R. Kawamori (2002)
Diabetes 51, 238-242
   Abstract »    Full Text »    PDF »
Implications of the Human Genome for Understanding Human Biology and Medicine.
G. Subramanian, M. D. Adams, J. C. Venter, and S. Broder (2001)
JAMA 286, 2296-2307
   Abstract »    Full Text »    PDF »
The Viral CC Chemokine-binding Protein vCCI Inhibits Monocyte Chemoattractant Protein-1 Activity by Masking Its CCR2B-binding Site.
C. G. Beck, C. Studer, J.-F. Zuber, B. J. Demange, U. Manning, and R. Urfer (2001)
J. Biol. Chem. 276, 43270-43276
   Abstract »    Full Text »    PDF »
Effects of CCR5-{Delta} 32, CCR2-64I, and SDF-1 3'A Alleles on HIV-1 Disease Progression: An International Meta-Analysis of Individual-Patient Data.
J. P.A. Ioannidis, P. S. Rosenberg, J. J. Goedert, L. J. Ashton, T. L. Benfield, S. P. Buchbinder, R. A. Coutinho, J. Eugen-Olsen, T. Gallart, T. L. Katzenstein, et al. (2001)
Ann Intern Med 135, 782-795
   Abstract »    Full Text »    PDF »
Frequent Substitution Polymorphisms in African Green Monkey CCR5 Cluster at Critical Sites for Infections by Simian Immunodeficiency Virus SIVagm, Implying Ancient Virus-Host Coevolution.
S. E. Kuhmann, N. Madani, O. M. Diop, E. J. Platt, J. Morvan, M. C. Muller-Trutwin, F. Barre-Sinoussi, and D. Kabat (2001)
J. Virol. 75, 8449-8460
   Abstract »    Full Text »    PDF »
Mechanisms Involved in Stimulation of Human Immunodeficiency Virus Type 1 Replication by Aminooxypentane RANTES.
A. J. Marozsan, V. S. Torre, M. Johnson, S. C. Ball, J. V. Cross, D. J. Templeton, M. E. Quinones-Mateu, R. E. Offord, and E. J. Arts (2001)
J. Virol. 75, 8624-8638
   Abstract »    Full Text »    PDF »
Results from a Genome-wide Search for Predisposing Genes in Sarcoidosis.
M. SCHURMANN, P. REICHEL, B. MULLER-MYHSOK, M. SCHLAAK, J. MULLER-QUERNHEIM, and E. SCHWINGER (2001)
Am. J. Respir. Crit. Care Med. 164, 840-846
   Abstract »    Full Text »    PDF »
The coreceptor mutation CCR5Delta 32 influences the dynamics of HIV epidemics and is selected for by HIV.
A. D. Sullivan, J. Wigginton, and D. Kirschner (2001)
PNAS
   Abstract »    Full Text »    PDF »
CCAAT-Enhancer-Binding Protein {beta} (C/EBP{beta}) Activates CCR5 Promoter: Increased C/EBP{beta} and CCR5 in T Lymphocytes from HIV-1-Infected Individuals.
M. Rosati, A. Valentin, D. J. Patenaude, and G. N. Pavlakis (2001)
J. Immunol. 167, 1654-1662
   Abstract »    Full Text »    PDF »
Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis.
W. Peters, H. M. Scott, H. F. Chambers, J. L. Flynn, I. F. Charo, and J. D. Ernst (2001)
PNAS 98, 7958-7963
   Abstract »    Full Text »    PDF »
Effect of a Single Amino Acid Change in MHC Class I Molecules on the Rate of Progression to AIDS.
X. Gao, G. W. Nelson, P. Karacki, M. P. Martin, J. Phair, R. Kaslow, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, et al. (2001)
N. Engl. J. Med. 344, 1668-1675
   Abstract »    Full Text »    PDF »
Host Determinants in HIV Infection and Disease: Part 2: Genetic Factors and Implications for Antiretroviral Therapeutics.
C. M. Hogan and S. M. Hammer (2001)
Ann Intern Med 134, 978-996
   Abstract »    Full Text »    PDF »
A Common Stromal Cell-Derived Factor-1 Chemokine Gene Variant is Associated With the Early Onset of Type 1 Diabetes.
D. Dubois-Laforgue, H. Hendel, S. Caillat-Zucman, J.-F. Zagury, C. Winkler, C. Boitard, and J. Timsit (2001)
Diabetes 50, 1211-1213
   Abstract »    Full Text »
Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha : Impact on the epidemiology of the HIV-1 pandemic.
E. Gonzalez, R. Dhanda, M. Bamshad, S. Mummidi, R. Geevarghese, G. Catano, S. A. Anderson, E. A. Walter, K. T. Stephan, M. F. Hammer, et al. (2001)
PNAS 98, 5199-5204
   Abstract »    Full Text »    PDF »
Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity.
P. O. Flores-Villanueva, E. J. Yunis, J. C. Delgado, E. Vittinghoff, S. Buchbinder, J. Y. Leung, A. M. Uglialoro, O. P. Clavijo, E. S. Rosenberg, S. A. Kalams, et al. (2001)
PNAS
   Abstract »    Full Text »
Naturally Occurring Deletional Mutation in the C-Terminal Cytoplasmic Tail of CCR5 Affects Surface Trafficking of CCR5.
T. Shioda, E. E. Nakayama, Y. Tanaka, X. Xin, H. Liu, A. Kawana-Tachikawa, A. Kato, Y. Sakai, Y. Nagai, and A. Iwamoto (2001)
J. Virol. 75, 3462-3468
   Abstract »    Full Text »
Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel disease.
J Hampe, N J Lynch, S Daniels, S Bridger, A J S Macpherson, P Stokkers, A Forbes, J E Lennard-Jones, C G Mathew, M E Curran, et al. (2001)
Gut 48, 191-197
   Abstract »    Full Text »    PDF »
Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140.
A. Trkola, T. J. Ketas, K. A. Nagashima, L. Zhao, T. Cilliers, L. Morris, J. P. Moore, P. J. Maddon, and W. C. Olson (2001)
J. Virol. 75, 579-588
   Abstract »    Full Text »
Donor- and Ligand-Dependent Differences in C-C Chemokine Receptor 5 Reexpression.
R. Sabbe, G. R. Picchio, C. Pastore, O. Chaloin, O. Hartley, R. Offord, and D. E. Mosier (2001)
J. Virol. 75, 661-671
   Abstract »    Full Text »
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10.
H. D. Shin, C. Winkler, J. C. Stephens, J. Bream, H. Young, J. J. Goedert, T. R. O'Brien, D. Vlahov, S. Buchbinder, J. Giorgi, et al. (2000)
PNAS 97, 14467-14472
   Abstract »    Full Text »    PDF »
Characterization of Three nef-Defective Human Immunodeficiency Virus Type 1 Strains Associated with Long-Term Nonprogression.
D. I. Rhodes, L. Ashton, A. Solomon, A. Carr, D. Cooper, J. Kaldor, and N. Deacon (2000)
J. Virol. 74, 10581-10588
   Abstract »    Full Text »
Factors Impacting on Drug Choices: Issues for Developing Countries.
S. A SPECTOR (2000)
Ann. N.Y. Acad. Sci. 918, 346-350
   Abstract »    Full Text »    PDF »
Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4.
B. Shieh, Y.-E. Liau, P.-S. Hsieh, Y.-P. Yan, S.-T. Wang, and C. Li (2000)
Int. Immunol. 12, 1311-1318
   Abstract »    Full Text »    PDF »
Multiple nonfunctional alleles of CCR5 are frequent in various human populations.
C. Blanpain, B. Lee, M. Tackoen, B. Puffer, A. Boom, F. Libert, M. Sharron, V. Wittamer, G. Vassart, R. W. Doms, et al. (2000)
Blood 96, 1638-1645
   Abstract »    Full Text »    PDF »
Current Evidence and Future Directions for Targeting HIV Entry: Therapeutic and Prophylactic Strategies.
M. P. D'Souza, J. S. Cairns, and S. F. Plaeger (2000)
JAMA 284, 215-222
   Abstract »    Full Text »    PDF »
Polymorphism in the Interleukin-4 Promoter Affects Acquisition of Human Immunodeficiency Virus Type 1 Syncytium-Inducing Phenotype.
E. E. Nakayama, Y. Hoshino, X. Xin, H. Liu, M. Goto, N. Watanabe, H. Taguchi, A. Hitani, A. Kawana-Tachikawa, M. Fukushima, et al. (2000)
J. Virol. 74, 5452-5459
   Abstract »    Full Text »
Unusual Polymorphisms in Human Immunodeficiency Virus Type 1 Associated with Nonprogressive Infection.
L. Alexander, E. Weiskopf, T. C. Greenough, N. C. Gaddis, M. R. Auerbach, M. H. Malim, S. J. O'Brien, B. D. Walker, J. L. Sullivan, and R. C. Desrosiers (2000)
J. Virol. 74, 4361-4376
   Abstract »    Full Text »
Variant genotypes of Fcgamma RIIIA influence the development of Kaposi's sarcoma in HIV-infected men.
T. L. nbecher, C. B. Foster, S. Zhu, D. Venzon, S. M. Steinberg, K. Wyvill, J. A. Metcalf, S. S. Cohen, J. Kovacs, R. Yarchoan, et al. (2000)
Blood 95, 2386-2390
   Abstract »    Full Text »    PDF »
International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors.
P. M. Murphy, M. Baggiolini, I. F. Charo, C. A. Hebert, R. Horuk, K. Matsushima, L. H. Miller, J. J. Oppenheim, and C. A. Power (2000)
Pharmacol. Rev. 52, 145-176
   Abstract »    Full Text »    PDF »
Cloning of a Novel Chemoattractant Receptor Activated by Leukotriene B4 and Used by Human Immunodeficiency Virus Type 1 to Infect CD4-positive Immune Cells . A Therapeutic Connection to Asthma?.
C. OWMAN, A. SABIRSH, A. GARZINO-DEMO, and F. COCCHI (2000)
Am. J. Respir. Crit. Care Med. 161, S56-61
   Full Text »    PDF »
5' Nuclease Assays for the Loci CCR5-+/{Delta}32, CCR2-V64I, and SDF1-G801A Related to Pathogenesis of AIDS.
C.-C. Yuan, R. J. Peterson, C.-D. Wang, F. Goodsaid, and D. J. Waters (2000)
Clin. Chem. 46, 24-30
   Abstract »    Full Text »    PDF »
Multiple Charged and Aromatic Residues in CCR5 Amino-terminal Domain Are Involved in High Affinity Binding of Both Chemokines and HIV-1 Env Protein.
C. Blanpain, B. J. Doranz, J. Vakili, J. Rucker, C. Govaerts, S. S. W. Baik, O. Lorthioir, I. Migeotte, F. Libert, F. Baleux, et al. (1999)
J. Biol. Chem. 274, 34719-34727
   Abstract »    Full Text »    PDF »
A Polymorphism in the Regulatory Region of the CC-Chemokine Receptor 5 Gene Influences Perinatal Transmission of Human Immunodeficiency Virus Type 1 to African-American Infants.
L. G. Kostrikis, A. U. Neumann, B. Thomson, B. T. Korber, P. McHardy, R. Karanicolas, L. Deutsch, Y. Huang, J. F. Lew, K. McIntosh, et al. (1999)
J. Virol. 73, 10264-10271
   Abstract »    Full Text »
Genotyping of the CCR5 Chemokine Receptor by Isothermal NASBA Amplification and Differential Probe Hybridization.
J. W. Romano, S. Tetali, E. M. Lee, R. N. Shurtliff, X. P. Wang, S. Pahwa, M. H. Kaplan, and C. C. Ginocchio (1999)
Clin. Vaccine Immunol. 6, 959-965
   Abstract »    Full Text »    PDF »
Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes.
E. Gonzalez, M. Bamshad, N. Sato, S. Mummidi, R. Dhanda, G. Catano, S. Cabrera, M. McBride, X.-H. Cao, G. Merrill, et al. (1999)
PNAS 96, 12004-12009
   Abstract »    Full Text »    PDF »
Search for the Mechanism of Genetic Variation in the pro Gene of Human Immunodeficiency Virus.
I. M. Rouzine and J. M. Coffin (1999)
J. Virol. 73, 8167-8178
   Abstract »    Full Text »    PDF »
Genetics of HIV-1infection: chemokine receptor CCR5 polymorphism and its consequences.
M. Carrington, M. Dean, M. P. Martin, and StephenJ. O'Brien (1999)
Hum. Mol. Genet. 8, 1939-1945
   Abstract »    Full Text »    PDF »
Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants.